A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than one in 5,000 people worldwide.
from Medical Xpress - latest medical and health news stories https://ift.tt/YQNty0T
